预约演示
更新于：2026-02-02
Lacosamide
拉考沙胺
更新于：2026-02-02
概要
基本信息
药物类型 小分子化药 |
别名 Erlosamide、Harkoseride、Lacosamide (JAN/USAN/INN) + [20] |
作用方式 阻滞剂 |
作用机制 钠通道阻滞剂 |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2008-08-29), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C13H18N2O3 |
InChIKeyVPPJLAIAVCUEMN-GFCCVEGCSA-N |
CAS号175481-36-4 |
关联
178
项与 拉考沙胺 相关的临床试验IRCT20250525065882N1
Evaluating the effect of Lacosamide treatment on the severity of headache attacks and CGRP-LI levels in people with migraine: A triple-blind randomized clinical trial
NCT06966830
A Multicenter, Prospective, Real-World Observational Study of Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus
CTR20251369
评估受试制剂拉考沙胺颗粒（规格：1 g: 0.1 g）与参比制剂拉考沙胺干糖浆（Vimpat® ）在健康成年参与者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性试验
100 项与 拉考沙胺 相关的临床结果
登录后查看更多信息
100 项与 拉考沙胺 相关的转化医学
登录后查看更多信息
100 项与 拉考沙胺 相关的专利（医药）
登录后查看更多信息
1,765
项与 拉考沙胺 相关的文献（医药）2026-04-01CLINICAL NEUROPHYSIOLOGY
Lacosamide modulates alpha-band network hubness: a quantitative EEG study in drug-Naïve focal epilepsy
Article
作者: Lazzaro, Vincenzo Di ; Sancetta, Biagio ; Placidi, Fabio ; Tombini, Mario ; Pulitano, Patrizia ; Matarrese, Margherita A G ; Ricci, Lorenzo ; Assenza, Giovanni ; Sferruzzi, Marco ; Izzi, Francesca
OBJECTIVE:
This study investigates pharmaco-EEG changes induced by Lacosamide (LCM) in drug-naive people with focal epilepsy (PwE) and explores the association between quantitative EEG (qEEG) and long-term clinical outcome.
METHODS:
We retrospectively identified 28 PwE and 25 healthy controls (HC). PwE were classified as seizure-free (SF) or non-seizure-free (NSF) after two years of LCM. EEGs were acquired before and ∼ 6 months after LCM. Power spectral density (PSD), amplitude-envelope correlation (AEC), and graph-theoretical metrics were compared between PwE and HC. Logistic regression was employed to examine the association between long-term outcomes (two-year seizure freedom) and qEEG metrics, in combination with clinical variables (sex, aetiology, seizure type, baseline EEG).
RESULTS:
LCM did not significantly modify global-averaged qEEG metrics (p > 0.05). Theta-band PSD was higher in PwE than HC. PwE exhibited higher alpha-band betweenness centrality (BtwC) than HC only before LCM (p = 0.007). Alpha-band BtwC provided the greatest discriminative value for seizure freedom (accuracy = 0.86; area under the curve [AUC] = 0.88).
CONCLUSIONS:
Although no significant differences were observed between pre- and post-LCM conditions, alpha-band BtwC showed a return toward a more physiological state after treatment, suggesting partial network normalization. Combining qEEG with clinical data improved long-term outcome discrimination, with alpha-band BtwC as the most relevant feature.
SIGNIFICANCE:
Graph-theoretical qEEG metrics offer additional insight into LCM's neurophysiological effects in focal epilepsy.
2026-03-01BIOCHEMICAL PHARMACOLOGY
Combination of two Na+ channel-inhibiting anticonvulsants lacosamide and phenytoin: An additive, synergistic, or antagonistic effect?
Article
作者: Lai, Yi-Chen ; Kuo, Chung-Chin ; Lin, Tien-Hung ; Yang, Ya-Chin ; Chen, Jian-Lin
The classic Na+channel-inhibiting anticonvulsants, such as phenytoin (DPH), and the new-generation lacosamide (LCM) selectively bind to the fast and slow inactivated states of the channel, respectively. The effect of a combination of the two anticonvulsants acting on the same protein with differently modulated receptors by neuronal activities, a possible clinical scenario, is investigated in native mouse neurons and heterologously-expressed human Na+channels. A combination of DPH and LCM does not necessarily show stronger inhibition on different neuronal epileptiform burst discharges than that of a single drug. There is more likely a doubly occupied channel and thus a supra-additive effect of the two drugs at prolonged weak and strong depolarization which moves most channels to the fast and slow inactivated states, respectively. However, single occupancy or mutual exclusion and thusan infra-additive effect may prevail with prolonged modest or short strong depolarization which presumably moves the channel chiefly to the intermediate inactivated states. Although there could be gaps between in vitro and clinical settings, the results implicate thata combination ofDPH and LCMfor seizure therapy is in general warranted, especially if the seizure discharges are characterized by prolonged strong membrane depolarization or its equivalents (a condition also endowingLCMthe best effect). However, cases of no increment, or even a decrement, in efficacy shall be carefully monitored. On the other hand,the rare cardiac adverse events reported for LCM use are not expected to increase with the combination because of the little additive effect on intermediate inactivated states. Abbreviations: AUC, area-under-the-curve; ANOVA, analysis of variance; CA1, cornu ammonis area 1 of the hippocampus; CHO-K1, Chinese hamster ovary K1; CI, combination index; DPH, phenytoin; EEG, electroencephalography; FBS, fetal bovine serum; GFP, green fluorescent protein; If, fast inactivated states; Ii, intermediate inactivated states; Is, slow inactivated states; LCM, lacosamide; Nav1.7, voltage-gated sodium channel subtype 1.7; SEM, standard error of the mean.
2026-02-01Neurology and Therapy
Lacosamide is Associated with a Higher Treatment Persistence at 12 Months than Brivaracetam and Perampanel Despite Similar Efficacy
Article
作者: Leggio, Ugo ; Dainese, Filippo ; Ferlazzo, Edoardo ; Falcicchio, Giovanni ; Foschi, Nicoletta ; Anzellotti, Francesca ; Politi, Cristina ; La Neve, Angela ; Belcastro, Vincenzo ; De Caro, Carmen ; Canafoglia, Laura ; Bonanni, Paolo ; Renna, Rosaria ; Operto, Francesca Felicia ; Lattanzi, Simona ; D'Aniello, Alfredo ; Russo, Emilio ; Roberti, Roberta ; Strigaro, Gionata ; Mattioli, Pietro ; Beretta, Simone ; Labate, Angelo ; Pauletto, Giada ; Gambardella, Antonio ; Nilo, Annacarmen ; Dono, Fedele ; Liguori, Claudio ; Pascarella, Angelo ; Pellegrino, Luciano ; Di Giacomo, Roberta ; Boero, Giovanni ; Di Gennaro, Gianfranco ; Giordano, Alfonso ; Maschio, Marta ; DiFrancesco, Jacopo C ; Di Gennaro, Giancarlo
INTRODUCTION:
Evidence directly comparing newer antiseizure medications (ASMs) is limited but crucial for guiding treatment decisions. This study compared the real-world effectiveness and tolerability of brivaracetam (BRV), lacosamide (LCM) and perampanel (PER) as add-on therapy in adults with epilepsy, applying a causal-inference extension of the COMPARE study. The aim of this approach was to overcome the limitations of standard multivariable analyses, better approximate causal effects, and reinforce the credibility of the results.
METHODS:
Data were retrospectively collected in the Italian multicentre COMPARE study. To emulate a randomized setting, we estimated multinomial propensity scores and applied stabilized inverse probability weights. The primary analysis used a log-logistic accelerated failure time model to estimate time-to-treatment discontinuation, adjusting for adverse events (AEs), clinical response and follow-up duration. Secondary analyses evaluated changes in total and concomitant drug load and tolerability over time.
RESULTS:
Among the 850 subjects included in this analysis (259, 240 and 351 receiving LCM, BRV and PER, respectively; 53.4% female; median age 43 years), the estimated probability of 12-month retention was highest for LCM (86.1%), followed by BRV (79.1%) and PER (75.4%). Long-term trends suggested convergence of PER and LCM retention, whereas BRV discontinuation remained higher. In the adjusted analyses, BRV and PER were associated with shorter time-to-treatment discontinuation than LCM, but this negative effect decreased over time, while the beneficial effect of clinical response strengthened. Total drug load increased across all groups but remained lowest for LCM; concomitant ASM load decreased, particularly among responders. AEs were mostly mild, with dizziness, irritability and somnolence the most common AEs. AE rates were initially higher for PER and BRV, but differences diminished over time.
CONCLUSION:
Treatment discontinuation in epilepsy emerges as a dynamic process shaped by both tolerability and clinical response. Early persistence was higher for LCM, whereas long-term retention was improved for BRV and PER. These results support a personalized approach to ASM selection that integrates early tolerability with sustained effectiveness.
342
项与 拉考沙胺 相关的新闻（医药）2026-01-30
2026-01-30
疫苗申请上市高管变更
2026-01-29
100 项与 拉考沙胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫 | 欧盟 | 2017-09-18 | |
| 癫痫 | 冰岛 | 2017-09-18 | |
| 癫痫 | 列支敦士登 | 2017-09-18 | |
| 癫痫 | 挪威 | 2017-09-18 | |
| 强直阵挛性癫痫 | 日本 | 2016-07-04 | |
| 特发全身性癫痫 | 澳大利亚 | 2009-07-20 | |
| 癫痫发作 | 澳大利亚 | 2009-07-20 | |
| 癫痫部分性发作 | 欧盟 | 2008-08-29 | |
| 癫痫部分性发作 | 冰岛 | 2008-08-29 | |
| 癫痫部分性发作 | 列支敦士登 | 2008-08-29 | |
| 癫痫部分性发作 | 挪威 | 2008-08-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 癫痫的复杂部分性发作 | 临床3期 | 美国 | 2007-08-01 | |
| 癫痫的复杂部分性发作 | 临床3期 | 澳大利亚 | 2007-08-01 | |
| 癫痫的复杂部分性发作 | 临床3期 | 奥地利 | 2007-08-01 | |
| 癫痫的复杂部分性发作 | 临床3期 | 加拿大 | 2007-08-01 | |
| 癫痫的复杂部分性发作 | 临床3期 | 丹麦 | 2007-08-01 | |
| 癫痫的复杂部分性发作 | 临床3期 | 法国 | 2007-08-01 | |
| 癫痫的复杂部分性发作 | 临床3期 | 德国 | 2007-08-01 | |
| 癫痫的复杂部分性发作 | 临床3期 | 爱尔兰 | 2007-08-01 | |
| 癫痫的复杂部分性发作 | 临床3期 | 意大利 | 2007-08-01 | |
| 癫痫的复杂部分性发作 | 临床3期 | 波兰 | 2007-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 48 | (Lacosamide: >=2 to <4 Years) | 齋夢鏇蓋夢構鏇鹹選糧 = 淵夢艱築選鹹蓋選鑰顧 餘構窪鹹襯齋積鬱繭繭 (艱構願鹹夢醖夢醖襯廠, 鬱齋餘遞簾顧憲憲築糧 ~ 構願鬱憲鬱艱壓衊餘鹹) 更多 | - | 2025-08-28 | ||
(Lacosamide: >=4 to <6 Years) | 齋夢鏇蓋夢構鏇鹹選糧 = 鏇選鬱衊齋淵廠餘艱艱 餘構窪鹹襯齋積鬱繭繭 (艱構願鹹夢醖夢醖襯廠, 積齋觸顧繭鑰齋觸鹹獵 ~ 憲壓築遞遞艱鹽齋廠遞) 更多 | ||||||
N/A | 207 | 顧範蓋窪廠齋獵鏇壓繭(遞範築願蓋顧襯積壓襯) = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. 襯範淵簾餘憲壓選觸衊 (網襯築積獵願觸糧窪獵 ) | 积极 | 2025-04-07 | |||
临床3期 | 239 | 膚鑰夢網襯齋觸繭淵鏇(鹹積願鬱積選醖鬱窪遞) = 膚蓋鹽鑰醖範壓觸觸壓 夢窪鏇遞餘鬱廠簾壓觸 (糧範製膚鹽鏇膚鬱製齋 ) 更多 | 积极 | 2024-12-01 | |||
临床3期 | 551 | Placebo | 衊蓋鹽醖餘觸製構衊鹽(顧窪積膚積鹽鑰醖鏇選) = 襯醖憲觸繭餘繭壓構齋 膚夢廠淵鏇鹹繭醖選艱 (範顧餘顧憲襯餘蓋憲範, 2.20) 更多 | - | 2024-03-22 | ||
临床3期 | 239 | 願蓋遞鑰願窪積獵範網 = 獵築鬱糧繭選壓選觸網 鏇範遞蓋艱醖齋網餘選 (願繭鹹鹽鹹艱選製積憲, 鹽鏇襯獵夢積壓糧憲醖 ~ 願築鹹遞艱蓋餘醖範窪) 更多 | - | 2023-12-14 | |||
临床2期 | - | Lacosamide up to 12 mg/kg/day or 600 mg/day | 糧範艱選廠壓願廠獵醖(築築膚廠鹽選繭顧醖鹹) = 獵選憲鏇繭製製鏇範築 鏇鹹蓋膚觸糧糧網簾選 (積構製衊製膚觸網夢選 ) | 积极 | 2023-11-01 | ||
N/A | 62 | 選淵鹹繭願範夢遞窪醖(鑰醖築壓糧淵糧糧壓淵) = Adverse events (AEs) were reported in 53%, none of which were attributed to lacosamide 選築齋襯構範窪顧蓋鏇 (構願糧獵膚築鏇鏇窪襯 ) 更多 | - | 2023-10-01 | |||
N/A | 二线 | 67 | 製遞獵膚衊獵醖鹽簾衊(積繭選觸艱襯製遞衊願) = 18 (26.9%) patient experienced bradycardia 繭網衊繭糧遞觸鏇憲蓋 (艱遞鏇積壓蓋鏇鬱積顧 ) 更多 | 积极 | 2023-09-04 | ||
N/A | - | 製衊衊襯餘鬱鬱觸願製(衊齋齋顧鏇鹽壓獵鑰範) = No side effects 憲鑰齋範顧襯鑰鑰顧鹽 (網遞膚鹹廠構鹽鹽鏇簾 ) 更多 | - | 2023-09-04 | |||
临床3期 | 371 | 選顧齋齋鑰淵蓋衊醖遞 = 選鏇淵襯顧簾艱簾簾繭 積夢積觸壓鑰衊願襯構 (廠獵製鏇簾觸鑰醖襯糧, 構衊夢鹽齋淵選鹹艱壓 ~ 襯鏇衊鹹觸鹹製壓選鑰) 更多 | - | 2023-07-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用